University of Malaya, Kuala Lumpur
Lung adenocarcinoma affected by antitumor activity of gefitinib
Published in Physician Law Weekly, June 28th, 2006
In a recent report published in the journal Respirology, researchers in Malaysia conducted a study "to describe the efficacy of monotherapy with the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib in patients with locally advanced and metastatic primary lung adenocarcinoma. A retrospective analysis was undertaken of patients who had locally advanced or metastatic lung adenocarcinoma treated with gefitinib 250 mg orally once daily until disease progression. All patients had either been...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
Source: Physician Law Weekly (2006-06-28)
More Articles from Physician Law Weekly
- American Association for the Study of Liver Diseases
Education and guidelines needed for genetic testing in liver disease - Avid Radiopharmaceuticals, Inc.
Avid Radiopharmaceuticals adds three industry veterans - Chimicles & Tikellis LLP
Chimicles & Tikellis LLP issues update on securities class actions against Discovery Laboratories - Federal University of Minas Gerais, Brazil
Researchers' work from Brazil, the United States and Mexico adds to obesity body of knowledge - Illumina, Inc.
Illumina appoints Christian Cabou senior vice president and general counsel - Kalorama Information
Report suggests critical care pharmaceuticals market peaks at $1.7 billion - More from this issue of Physician Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
